This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Abbott, BP & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corporation (SMID) and Crimson Wine Group, Ltd. (CWGL).
Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Misses Q4 Earnings Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.20% and 0.02%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $103.45, signifying a -0.22% move from its prior day's close.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
by Zacks Equity Research
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Abbott (ABT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.
Implied Volatility Surging for Abbot Laboratories (ABT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $103.95, signifying a -0.27% move from its prior day's close.
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
by Zacks Equity Research
UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
by Zacks Equity Research
Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.